INTELLIGENCE IN ACTION

Federal Government Issues Final Rule: Part D Plans Must Adopt a Real Time Benefit Tool

May 20, 2019

On May 16, the Centers for Medicare and Medicaid Services (CMS) issued its final rule: Medicare Advantage and Part D Drug Pricing Final Rule (CMS-4180-F).

We’ve been closely following the provision of the proposal aimed at accelerating the use of Real Time Benefit Tools (RTBTs), such as Surescripts Real-Time Prescription Benefit.

This technology gives prescribers visibility to cost and coverage information within their electronic health record (EHR). With it, they can choose the best, most affordable medication in collaboration with their patient during the office visit. This replaces the tedious manual process of retrospective prescription drug cost comparison, which all too often involves back-and-forth phone calls between the pharmacist, prescriber and patient.

The proposed rule required the adoption of at least one RTBT by January 1, 2020, but the government received feedback that the timeline was too aggressive. While we at Surescripts recommended that CMS forge ahead with their proposed timing in the interest of helping patients, the deadline was indeed pushed out a year to January 1, 2021.

From the final rule: “In order to accelerate the use of electronic Real Time Benefit Tools (RTBT) in the Part D program, CMS is requiring that each Part D plan adopt one or more RTBTs that are capable of integrating with at least one prescriber’s ePrescribing system or electronic health record (EHR), no later than January 1, 2021. RTBTs have the capability to inform prescribers when lower-cost alternative therapies are available under the beneficiary’s prescription drug benefit, which can improve medication adherence, lower prescription drug costs, and minimize beneficiary out-of-pocket costs.”

Regardless of the timing, we fully support the government in its efforts to leverage prescription price transparency at the point of care. Healthcare providers want to get off the phone and back to caring for their patients. And patients deserve to know their out-of-pocket cost before they leave their doctor’s office. We know that when they do, they’re more likely to start and stick with their medications.

We are reassured by the remarkable response we’ve seen from prescribers, with more than 150,000 already using our tool today. And the impact has been felt by patients with one saving more than $8,000 on a single prescription.

Learn more about Surescripts Real-Time Prescription Benefit solution and the positive impact prescription price transparency is making on the cost, quality and safety of American healthcare.

Related Articles

August 13, 2019

When Paperwork Comes Before Patients: Missing Key Information Complicates Specialty Prescribing

William J. Mayo, MD, (“Doctor Will”) said, “The best interest of the patient is the only interest to be considered, and in order that the sick may have the benefit of advancing knowledge, union of forces is necessary.”

Read more...
July 25, 2019

How Aurora Health Care Used Electronic Prior Authorization To Cut Clinic Staff Overtime By More Than Half

The reality of traditional prior authorization is this: While the prescriber, the PBM and the pharmacy team spend valuable time making phone calls, tracking down information and filling out forms, the patient waits. And waits. And waits. In other words, patients face delays in receiving their prescriptions, clinicians lose valuable time and the health system faces mounting overtime costs.

Read more...
July 22, 2019

The Onerous Specialty Prescribing Process Hurts Patients and Tires Doctors. What Can Be Done?

It really should be so simple—getting a patient on a specialty therapy. The doctor and patient have chosen the best therapy; the patient is in great need. But according to our recent survey of 500 prescribers, on average it can take nearly 8 days to start patients on specialty medications, which are used to treat challenging chronic conditions such as cancer, multiple sclerosis and rheumatoid arthritis. 

Read more...

INTELLIGENCE IN ACTION, DELIVERED TO YOUR INBOX